# Effects of Whole‐Body Cryotherapy Combined With Conventional Obesity Management Versus Obesity Management Alone: A Clinical Trial

**Authors:** Jari E. Karppinen, Laura Suojanen, Sini Heinonen, Sanna Kaye, Birgitta W. van der Kolk, James W. White, Janne Orava, Seung Hyuk T. Lee, Eugené Dillon, Maheswary Muniandy, Aila Rissanen, Carel W. le Roux, Neil Docherty, Päivi Pajukanta, Kirsi A. Virtanen, Kirsi H. Pietiläinen

PMC · DOI: 10.1002/oby.70019 · Obesity (Silver Spring, Md.) · 2025-09-03

## TL;DR

This study tested if whole-body cryotherapy, combined with lifestyle changes, improves weight loss and metabolism in people with obesity.

## Contribution

The study is one of the first to evaluate whole-body cryotherapy's effects on brown fat activation and metabolic outcomes in obesity management.

## Key findings

- Whole-body cryotherapy did not significantly enhance weight loss compared to lifestyle changes alone.
- Cryotherapy showed improvements in fasting glucose and LDL cholesterol at 5 months.
- No significant differences were found in brown adipose tissue activation or energy expenditure between groups.

## Abstract

To investigate whether whole‐body cryotherapy (WBC) enhances weight loss, brown adipose tissue (BAT) activation, and metabolic outcomes during obesity management.

Nineteen adults with obesity were assigned to a 12‐month lifestyle‐based obesity management intervention with 28 WBC sessions (−110°C, 3–4 min, ~2 × week) over the first 5 months (CRYO, n = 10) or the intervention without WBC (CON, n = 9). The primary outcome was weight loss (5 and 12 months). Secondary outcomes included BAT glucose uptake and whole‐body energy expenditure during cold stimulation (5 months), clinical parameters, subcutaneous adipose tissue transcriptomics, and skeletal muscle proteomics (5 and 12 months).

Weight loss in the CRYO group was 11.9% at 5 months and 9.9% at 12 months, compared to 11.5% and 8.0% in the CON group (p ≥ 0.54 for between‐group differences). No significant between‐group differences appeared in BAT glucose uptake, energy expenditure, adipose tissue transcriptomics, or skeletal muscle proteomics changes. However, at 5 months, the CRYO group showed greater reductions in fasting glucose (0.41 mmol/L, p = 0.026) and LDL cholesterol (0.44 mmol/L, p = 0.034).

WBC did not significantly enhance weight loss, activate BAT, or alter most metabolic responses during conventional obesity management. Further research is needed to confirm whether WBC benefits glucose and cholesterol metabolism.

Trial Registration:
ClinicalTrials.gov: NCT01312090

## Linked entities

- **Diseases:** obesity (MONDO:0011122)

## Full-text entities

- **Diseases:** Weight loss (MESH:D015431), Obesity (MESH:D009765)
- **Chemicals:** glucose (MESH:D005947), CRYO (-), cholesterol (MESH:D002784)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12559775/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12559775/full.md

## References

45 references — full list in the complete paper: https://tomesphere.com/paper/PMC12559775/full.md

---
Source: https://tomesphere.com/paper/PMC12559775